Skin excoriation disorder: pathophysiology and treatment

Authors

  • María Soledad Benítez Faculty of Medicine, University of Buenos Aires (UBA), City of Buenos Aires, Argentina
  • Julieta Soledad Fischer Francisco Javier Muñiz Hospital, City of Buenos Aires, Argentina
  • María Emilia Candiz Francisco Javier Muñiz Hospital, City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/bcpepy61

Keywords:

excoriation disorder, skin picking disorder, self-injurious behavior, pathophysiology, therapeutics, N-Acetylcysteine, memantine

Abstract

Skin picking disorder (SPD; excoriation disorder) is a psychiatric condition characterized by recurrent, compulsive manipulation of the skin, resulting in tissue damage. This condition predominantly affects women, with symptom onset typically coinciding with puberty, influenced by physiological and emotional changes, as well as concomitant dermatoses such as acne.

The most frequently affected sites include the face, arms, and hands, localized to easily accessible areas, with a notable predominance on the non-dominant side of the body. These repetitive behaviors are considered a form of behavioral addiction, given their association with a premonitory urge, a sense of gratification during the act, and a persistent, compulsive pattern of repetition.

Neurobiologically, cortico-striatal-thalamo-cortical (CSTC) circuits -which mediate habit formation and reward processing- are implicated in SPD pathogenesis. A considerable proportion of patients initially seek medical attention from dermatologists. A patient-centered approach, emphasizing empathetic engagement, is critical to establish therapeutic rapport and optimize outcomes.

Cognitive-behavioral therapy (CBT), particularly habit reversal training, remains the first-line psychological intervention, aiming to replace maladaptive behaviors with more adaptive alternatives. Pharmacotherapy guidelines prioritize serotonergic agents (e.g., SSRIs) for their modulatory effects on impulsivity. In treatment-refractory cases (∼30%), emerging evidence supports glutamatergic modulation with N-acetylcysteine (1,200-2,400 mg/day) or memantine (10-20 mg/day) as viable alternatives.

Author Biographies

  • María Soledad Benítez, Faculty of Medicine, University of Buenos Aires (UBA), City of Buenos Aires, Argentina

    Medical Doctor from the Specialist Career in Dermatology

  • Julieta Soledad Fischer, Francisco Javier Muñiz Hospital, City of Buenos Aires, Argentina

    Dermatologist, Dermatology Service

  • María Emilia Candiz, Francisco Javier Muñiz Hospital, City of Buenos Aires, Argentina

    Dermatologist, Dermatology Service

References

I. Phillips KA. Anxiety, obsessive-compulsive spectrum, posttraumatic, and dissociative disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013;254-257.

II. Okumuş HG, Akdemir D. Body focused repetitive behavior disorders. Behavioral models and neurobiological mechanisms. Turk Psikiyatri Derg. 2023;34:50-59.

III. Sheppard NP, O’Loughlin S, Malone JP. Psychogenic skin disease: a review of 35 cases. Br J Psychiatry. 1986;149:636-643.

IV. Macmaster FP, Rosenberg DR. Glutamate and the treatment of obsessive-compulsive disorder. Psychopharmacol Rev. 2010;45:33-40.

V. Odlaug BL, Hampshire A, Chamberlain SR, Grant JE. Abnormal brain activation in excoriation (skin-picking) disorder: evidence from an executive planning fMRI study. Br J Psychiatry. 2016;208:168-174.

VI. Yadav S, Narang T, Kumaran MS. Psychodermatology: a comprehensive review. Indian J Dermatol Venereol Leprol. 2013;79:176-192.

VII. Torales J, Díaz NR, Barrios I, Navarro R, et al. Psychodermatology of skin picking (excoriation disorder): a comprehensive review. Dermatol Ther. 2020;33:e13661.

VIII. Romaní de Gabriel J, Chesa-Vela D. Psicodermatología en atención primaria. Piel. (Barc). 2005;20:282-289.

IX. Wong JW, Nguyen TV, Koo JY. Primary psychiatric conditions: dermatitis artefacta, trichotillomania and neurotic excoriations. Indian J Dermatol. 2013;58:44-48.

X. Ständer S, Zeidler C, Magnolo N, Raap U, et al. Clinical management of pruritus. J Dtsch Dermatol Ges. 2015;13:101-115.

XI. Huang Y, Weng Y, Lan L, Zhu C, et al. Insight in obsessive-compulsive disorder: conception, clinical characteristics, neuroimaging, and treatment. Psychoradiology. 2023;3.

XII. Valdivieso s, Ramírez C. El insight en psicoanálisis y sus dimensiones. Rev Chil Neuro Psiquiatr. 2002;40.

XIII. Andrén P, Jakubovski E, Murphy TL, Woitecki K, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part II: Psychological interventions. Eur Child Adolesc Psychiatry. 2022;3:403-423.

XIV. Liu S, Li Y, Cui Y. Review of habit reversal training for tic disorders. Pediatr Investig. 2020;4:127-132.

XV. Dunbar AB, Magid M, Reichenberg JS. Habit reversal training for body-focused repetitive behaviors: a practical guide for the dermatologist. G Ital Dermatol Venereol. 2018;153:557-566.

XVI. Whiting C, Azim SA, Friedman A. Updates in the treatment of body-focused repetitive disorders. J Drugs Dermatol. 2023;22:1069-1070.

XVII. Albert U, Marazziti D, Di Salvo G, Solia F, et al. A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy. Curr Med Chem. 2018;25:5647-5661.

XVIII. Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 2017;317:1358-1367.

XIX. Janeczek M, Moy L, Riopelle A, Vetter O, et al. The potential uses of N-acetylcysteine in dermatology: a review. J Clin Aesthet Dermatol. 2019;12:20-26.

XX. Adil M, Amin SS, Mohtashim M. N-acetylcysteine in dermatology. Indian J Dermatol Venereol Leprol. 2018;84:652-659.

XXI. Nwankwo CO, Jafferany M. N-acetylcysteine in psychodermatological disorders. Dermatol Ther. 2019;32: e13073.

XXII. Oliver G, Dean O, Camfield D, Blair-West S, et al. N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clin Psychopharmacol Neurosci. 2015;13:12-24.

XXIII. Lee DK, Lipner SR. The potential of N-acetylcysteine for treatment of trichotillomania, excoriation disorder, onychophagia, and onychotillomania: an updated literature review. Int J Environ Res Public Health. 2022;19:6370.

XXIV. Grant JE, Chamberlain SR, Redden SA, Leppink EW, et al. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73:490-496.

XXV. Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother. 2004;2:303-312.

XXVI. Wilcock G, Mobius HJ, Stoffler A; MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17:297-305.

XXVII. Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis. Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019;282:112602.

XXVIII. Grant JE, Chesivoir E, Valle S, Ehsan D, et al. Double-blind placebo-controlled study of memantine in trichotillomania and skin-picking disorder. Am J Psychiatry. 2023;180:348-356.

XXIX. Askari S, Mokhtari S, Shariat SV, Shariati B, et al. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder. A double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry. 2022;22:34.

Downloads

Published

2026-04-28

Issue

Section

Continuing Medical Education